Sonova Holding AG focuses on long-term strategy, shares backed by hearing health demand

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 13:17.

Sonova Holding AG (CH0012549785) positions its business model firmly in the long-term hearing health market. The Swiss group is listed on SIX Swiss Exchange, serving a structurally growing global demand for hearing care solutions as demographic and lifestyle trends support the shares.

Long-term hearing care strategy

Sonova Holding AG pursues a long-term strategy built around hearing aids, cochlear implants, and audiological care services, targeting both aging populations and younger users with noise-related hearing loss worldwide. The company emphasizes innovation, clinical performance, and service networks to deepen customer relationships over many years.

The group operates under brands such as Phonak and Unitron, using a vertically integrated model that combines product development, manufacturing, and retail audiology networks, which can stabilize cash flows over economic cycles. Its strategy centers on recurring replacement of hearing devices and ongoing service, underpinning the durability of the stock without relying on short-term trading catalysts.

Position in global healthcare sector

Sonova competes in the global hearing care sector alongside companies such as Demant and GN Store Nord, positioning itself in the broader healthcare and medical technology segment rather than consumer electronics. This sector focus is relevant for long-term investors who view hearing care as part of essential health services.

The company benefits from medical reimbursement frameworks in key markets, including Europe and North America, while also serving private pay customers seeking premium technology and comfort. Its exposure to healthcare spending and insurance mechanisms differentiates the shares from more cyclical industrial peers and links performance to health budgets and clinical practice trends.

What the company sells

Sonova Holding AG generates its revenue primarily from advanced hearing aids, cochlear implants, and related audiological services, leveraging its Phonak and Unitron brands to serve patients through a mix of wholesale and retail channels. These devices and services are typically prescribed and fitted by hearing care professionals, reinforcing a medically anchored business model.

Where the stock trades

Sonova Holding AG shares trade on SIX Swiss Exchange in Zurich, reflecting their status as a Swiss healthcare and medical technology stock; a current traded price in Swiss francs was not verifiably available at the time of writing, so no specific price level is stated.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.